# primary vitreoretinal lymphoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/primary-vitreoretinal-lymphoma

> 2 upcoming FDA catalysts in primary vitreoretinal lymphoma: icm adx-2191 injection (ALDX) on December 2029 (primary completion); icm adx-2191 injection (ALDX) on Dec 2029 to Mar 2030 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2023 | [Methotrexate Preservative Free (methotrexate) complete response letter (CRL)](https://sec-api.dev/pdufa/methotrexate) | ALDX | primary vitreoretinal lymphoma | completed, complete response letter | "In June 2023, we received a Complete Response Letter for our New Drug Application ("NDA") for ADX-2191 for the treatment of primary vitreoretinal lymphoma ("PVRL"), which stated that there was a lack of substantial evidence of effectiveness due to a lack of adequate and well-controlled investigations." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526453537/aldx-20261109.htm)) |
| December 2029 | [Icm adx-2191 injection primary completion](https://sec-api.dev/pdufa/icm-adx-2191) | ALDX | Primary Vitreoretinal Lymphoma | scheduled | "NCT07402876 (A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Aldeyra Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07402876)) |
| Dec 2029 to Mar 2030 | [Icm adx-2191 injection topline data readout](https://sec-api.dev/pdufa/icm-adx-2191) | ALDX | Primary Vitreoretinal Lymphoma | scheduled | "NCT07402876 (A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Aldeyra Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07402876)) |

## Drugs

- [Methotrexate Preservative Free (methotrexate)](https://sec-api.dev/pdufa/methotrexate) (PFE)
- [Icm adx-2191 injection](https://sec-api.dev/pdufa/icm-adx-2191) (ALDX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/primary-vitreoretinal-lymphoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "primary vitreoretinal lymphoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/primary-vitreoretinal-lymphoma

```bibtex
@misc{secapidev_indications_primary_vitreoretinal_lymphoma_20261116,
  title        = {primary vitreoretinal lymphoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/primary-vitreoretinal-lymphoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_primary_vitreoretinal_lymphoma_20261116","title":"primary vitreoretinal lymphoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/primary-vitreoretinal-lymphoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
